miR-106b suppresses pathological retinal angiogenesis

• Published in: Aging (Albany, NY.) Vol. 12; no. 24; pp. 24836 - 24852
• Main Authors: Ménard, Catherine, Wilson, Ariel M, Dejda, Agnieszka, Miloudi, Khalil, Binet, François, Crespo-Garcia, Sergio, Parinot, Célia, Pilon, Frédérique, Juneau, Rachel, Andriessen, Elisabeth Mma, Mawambo, Gaëlle, SanGiovanni, John Paul, De Guire, Vincent, Sapieha, Przemyslaw
• Format: Journal Article
• Language: English
• Published: United States Impact Journals 31.12.2020
• Subjects: Research Paper; age related macular degeneration; PERK; choroidal neovascularization; angiogenesis; miR-106b
• ISSN: 1945-4589; 1945-4589
• DOI: 10.18632/aging.202404

MicroRNAs are small non-coding RNAs that post-transcriptionally regulate gene expression. We recently demonstrated that levels of miR-106b were significantly decreased in the vitreous and plasma of patients with neovascular age-related macular degeneration (AMD). Here we show that expression of the miR-106b-25 cluster is negatively regulated by the unfolded protein response pathway of protein kinase RNA-like ER kinase (PERK) in a mouse model of neovascular AMD. A reduction in levels of miR-106b triggers vascular growth both and by inducing production of pro-angiogenic factors. We demonstrate that therapeutic delivery of miR-106b to the retina with lentiviral vectors protects against aberrant retinal angiogenesis in two distinct mouse models of pathological retinal neovascularization. Results from this study suggest that miRNAs such as miR-106b have the potential to be used as multitarget therapeutics for conditions characterized by pathological retinal angiogenesis.